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We present three novel mutations in the G6PD gene and discuss the changes they cause in the 
3-dimensional structure of the enzyme: 573C→G substitution that predicts Phe to Leu at position 
191 in the C-terminus of helix αe, 851T→C mutation which results in the substitution 284Val→
→Ala in the β+α domain close to the C-terminal part of helix αj, and 1175T→C substitution that 
predicts Ile to Thr change at position 392.
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INTRODUCTION
Glucose-6-phosphate dehydrogenase (G6PD) 
is the key enzyme of the pentose phosphate pathway 
whose main physiological function in red blood cells 
is to produce NADPH essential for the protection 
of the cells against oxidative stress. The G6PD gene 
is X-linked and G6PD deficiency is the most com-
mon human enzyme defect, being present in over 
400 million people worldwide. Most of the affected 
people do not complain of the defect. However, they 
may develop hemolysis after ingestion of fava beans, 
some drugs or during infection. Neonatal jaundice 
is often observed in affected families. Chronic non-
spherocytic hemolytic anemia (CNSHA) is a rare but 
more severe clinical type of G6PD deficiency. Ane-
mia and an increased reticulocyte count are persist-
ent throughout the whole life. In some compensated 
cases there is no anemia but reticulocytosis is still 
present (chronic nonspherocytic hemolytic disease). 
Chronic hemolysis may be aggravated by all factors 
able to provoke hemolysis in asymptomatic G6PD-
deficient subjects (Beutler, 1994). 
Until now, more than 130 mutations in the 
G6PD gene have been identified. Most of the mu-
tations detected so far are point mutations causing 
single amino acid substitutions (Mehta et al., 2000). 
The three-dimensional structure of human G6PD 
(mutant Canton) has been determined, so it is possi-
ble to establish a structure–function relationship be-
tween the identified mutations and the phenotypes 
of the patients (Au et al., 2000).
In this report we describe three new missense 
mutations in G6PD-deficient patients from three un-
related families.
MATERIALS AND METHODS
Case description. Family #1. A 43-year old 
Georgian male was transfused at the age of 5 be-
cause of anemia of unknown etiology. At present, he 
*This paper is dedicated to Professor Tadeusz Chojnacki from the Institute of Biochemistry and Biophysics, Polish Acad-
emy of Sciences in Warsaw on the occasion of the 50th anniversary of his scientific activity and 75th birthday.
Correspondence: Beata Burzynska, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, A. Pawińskiego 
5A, 02-106 Warszawa, Poland, phone: (48) 22 592 1214, fax: (48) 22 658 4636; e-mail: atka@ibb.waw.pl
Abbreviations: Ag, antigen; G6PD, glucose-6-phosphate dehydrogenase; HB, hepatitis B.
Vol. 54 No. 4/2007, 877–881
on-line at: www.actabp.pl
878            2007M. Maciag and others
does not manifest any signs or symptoms of anemia. 
His blood study revealed an increased reticulocyte 
count and normal serum bilirubin concentration 
(Table 1). Erythrocyte G6PD deficiency was diag-
nosed. The studies were done because of anemia of 
his nearly 3-year old daughter. She was admitted to 
the hospital with abdominal pain and jaundice. Her 
urine was dark and stools were normal. She had no 
fever. Her liver was palpable 3 cm below the right 
costal margin. One day before the onset of the dis-
ease she had ingested fava beans. She had had a his-
tory of neonatal jaundice with serum bilirubin con-
centration of 205 µmol/L. On admission her blood 
study revealed anemia (Hb 99.5 g/L, retics 3.2%) 
and increased bilirubin concentration (total bilirubin 
107.7 µmol/L). Hepatotropic virus infection (HBV, 
HCV) was excluded. Her recovery was uncompli-
cated. Four months later her blood study exhibited 
no anemia, however, her parents noticed a yellow 
tint of her scleras that occurred intermittently. G6PD 
deficiency was diagnosed. Results of her latest blood 
study at the age of 5 are presented in Table 1. 
Family #2. A 40-year old Polish male had been 
under medical control since the age of 2, when a 
hemolytic crisis in the course of pneumonia devel-
oped. A diagnosis of erythrocyte G6PD deficiency 
was established. After recovery his blood picture 
was always normal and his physical and mental 
development were also normal. He kept a diet: he 
avoided fava beans and other podded plants. He 
was warned against taking some hemolytic drugs. 
At the age of 35 he had an acute hemolytic anemia 
after a Chinese dish containing some pulses. He was 
admitted to the hospital. His hemoglobin concentra-
tion was 100 g/L, mean cell volume 112 fL, total bi-
lirubin 51.3 µmol/L and LDH 790 U/L. HBs Ag and 
HCV Ab were not detected. At present, he has no 
evident anemia but increased serum bilirubin con-
centration and reticulocyte count indicate for a mild 
and almost compensated hemolytic disease (Ta-
ble 1). His 10-year old daughter has never had ane-
mia or icterus, even during infection and fever, but 
her reticulocyte count is increased. Her G6PD activ-
ity of red cells is decreased (Table 1). 
Family #3. A 6-year old Polish boy had been 
under medical control since birth. He was trans-
fused at the age of 2 weeks, and then at the age of 
2 months due to prominent anemia with jaundice. 
When the patient was 4 months old, G6PD deficien-
cy was first diagnosed by a semi-quantitative meth-
od and was later confirmed quantitatively (Table 1). 
Since then, he has been under the care of a hema-
tology clinic and had several transient episodes of 
minor anemia and jaundice, but he did not require 
transfusion. His physical and mental development 
was normal. He kept a diet and his parents were 
warned against giving him hemolytic drugs. At the 
age of 5 he had an episode of acute hemolytic ane-
mia during viral infection. At the age of 6, during 
febrile infection, he had hemolytic crisis which re-
sulted in hospitalization and two transfusions. He 
is currently well and his anemia is almost compen-
sated, however, other laboratory data indicate for a 
persistent hemolytic process (Table 1).
DNA isolation, amplification and sequenc-
ing. Blood samples for this study were obtained 
after informed consent of the patients. DNA Isola-
tion Kit for Blood/Bone Marrow/Tissue (Roche Diag-
nostics GmbH, Germany) was used to isolate DNA 
from leukocytes. 
G6PD gene exons 2 to 13 were amplified by 
polymerase chain reaction (PCR). Each reaction mix-
ture contained 10–250 ng of human genomic DNA, 
2.5 µl of 10 × PCR buffer, 1.0 µL of each primer (10 
Table 1. Hematologic parameters, G6PD activity and molecular data
Patient Family #1 Family #2 Family #3
male his daughter male his daughter boy
Age (years) 43 5 40 10 6
Hb (g/L) 151 126 147 130 114
RBC (x1012/L) 4.68 4.59 4.12 4.76 3.54
MCV (fL) 100 82 101 81 91.8
Retics (% of RBC) 3.3 0.7 5.7 4.7 2.9
Unc Bilir (µmol/L) 13.6 25.4 37.8 6.0 46
LDH (U/L) 247 378 194 223 536
Ferritin (µg/L) 188 19.4 1595 299 100
Fe (µmol/L) 25 28 22.4 11.3 16.5
UIBC (µmol/L) 40 59 31.2 27.4 N.D.*
G6PD (IU/g Hb)** 0.0 4.2 0.0 8.34 2.6
G6PD mutation 573C→G 851T→C 1175T→C
Amino acid substitution F191L V284A I392T
*Not determined; **Normal value 13.55 +/– 2.45 IU/g Hb according to Beutler (1971). 
Vol. 54       879Novel G6PD variants
pmol/µL) and 1 unit of enzyme (FastStart Taq DNA 
Polymerase, Roche Diagnostics GmbH, Germany) in 
a final volume of 25 µL. PCR was carried out using 
Mastercycler personal (Eppendorf) with 3-min dena-
turation step at 94°C, followed by 30 cycles of 45 s 
at 94°C, 45 s of annealing in the temperature appro-
priate for the primers, then the elongation at 72°C 
of appropriate time, and the final 5-min extension at 
72°C. PCR products were analyzed by agarose gel 
electrophoresis. The sequences of all primers and the 
annealing temperatures are available upon request. 
DNA fragments generated by PCR amplifica-
tion were purified using Qiaquick PCR Purification 
Kit (QIAGEN, Germany), and directly sequenced 
with BigDye Terminators and the appropriate prim-
ers using an ABI Prism 377 sequencer (Applied 
Biosystem, CA, USA). Restriction analysis with 
the use of TspGW1 (EURx), AatII (Fermentas) and 
MboI (Fermentas) enzymes was carried out to con-
firm the presence of the detected mutations (Fig. 1). 
PCR products (15 µL) were digested at 70°C (for 
the TspGW1 enzyme) and 37°C (for AatII and MboI) 
for 3 h.
Molecular model of human G6PD struc-
ture. The three-dimensional structure of human 
G6PD (the mutant Canton R459L) has been de-
termined (Au et al., 2000). To check the influence 
of the F191L, V284A and I392T mutations on the 
enzyme structure, models of the wild type and 
mutated proteins were obtained by simple re-
placement of Leu459 to Arg and Leu459 to Arg 
together with Phe191 to Leu, Val284 to Ala, or 
Ile392 to Thr, respectively (Fig. 2). The wild type 
and mutated structures were subjected to energy 
minimization in vacuo using CVFF forcefield as 
implemented in DISCOVER ver. 2004.1 (Accelrys, 
San Diego, USA).
RESULTS
Direct sequencing of the G6PD gene from the 
Georgian male revealed the presence of a previously 
undescribed 573C→G mutation located in exon 6 
which resulted in a phenylalanine to leucine substi-
tution at position 191. The presence of this mutation 
was confirmed with the restriction enzyme TspGW1 
(Fig. 1A). 
DNA sequencing of the G6PD gene from the 
Polish male showed another novel mutation located 
in exon 8. The 851T→C substitution predicts a va-
line to alanine change at position 284. The presence 
of this mutation was verified with the restriction en-
zyme AatII (Fig. 1B). 
DNA sequencing of the G6PD gene from the 
Polish boy revealed the presence of a previously un-
described 1175T→C substitution located in exon 10, 
predicting an isoleucine to threonine substitution at 
position 392. The presence of this mutation was con-
firmed with the restriction enzyme MboI (Fig. 1C). 
No other mutations were detected in the re-
maining exons or adjacent regions of the G6PD 
gene. The novel variants F191L, V284A and I392T 
were named G6PD Pedoplis-Ckaro, G6PD Piotrkow 
Figure 1. Pattern of restriction enzyme digests of PCR fragments of G6PD.
A, TspGWI digest of PCR fragment containing exons 6, 7 and 8 of G6PD; M, 100 bp ladder; wt, wild type; 1, proband. 
B, MboI digest of PCR fragment containing exons 9, 10, 11 and 12 of G6PD; M, 1 kb ladder; wt, wild type; 1, proband. 
C, AatII digest of PCR fragment containing exons 6, 7 and 8 of G6PD; M, 1 kb ladder; wt, wild type; 1, proband.
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and G6PD Krakow, respectively, after the patients’ 
place of origin.
DISCUSSION
All the novel variants described belong to 
class I, since all three patients have chronic hemo-
lysis. The patient with G6PD Pedoplis-Ckaro has a 
chronic nonspherocytic hemolytic disease without 
anemia. Hemolysis is more intensive in the patient 
with G6PD Piotrkow. His reticulocyte count is high-
er than that of the first patient and the compensation 
of hemolysis is not quite full. His serum ferritin con-
centration is high, probably as a result of intensive 
iron absorption stimulated by increased erythropoi-
esis in the bone marrow. However, the hemolytic 
process in both patients is mild. They lead normal 
life, both are married and professionally active. The 
boy with G6PD Krakow and chronic nonspherocytic 
hemolytic anemia has had frequent exacerbation of 
hemolysis provoked mainly by infections. Neverthe-
less, one should evaluate his hemolytic process also 
as a mild one.
F191 is located at the C-terminus of helix αe 
(Fig. 2A), outside the coenzyme binding site, far 
away from the dimer and tetramer interfaces. Two 
mutations adjacent to F191: H155N and N165D 
have been described earlier, and are recognized 
as class I and class II variants, respectively (Tang 
et al., 1992; Menounos et al., 2000). Known muta-
tions located at helix αe have been classified as 
class I variants: S179C, D176G and class II vari-
ants: S188F and D181V (Vulliamy et al., 1988; Beu-
tler et al., 1991; Hirono et al., 1994; Beutler et al., 
2002). F191 is not a highly conserved residue. The 
environment of this residue is hydrophobic, so re-
placement of the Phe by Leu, which is not much 
smaller, should not significantly affect the overall 
protein fold. This is confirmed by the energy min-
imization calculations for the wild type enzyme 
and the F191L mutant.
V284 is located in the β+α domain close to 
the C-terminal part of helix αj (Fig. 2A). Helix αj 
contains E287 and K290 forming salt bridges with 
K290 and E287, respectively, located in the neigh-
bouring subunit. These contacts stabilize tetramer 
formation. Several known mutations in the prox-
imity of V284 are classified as the class I variants: 
G274K, P276S, S278F, S278P and G447R, some as 
class II or class III variants: T279A, T279S, R285C, 
R285H, S448G, Q449H and D282H (Vulliamy et 
al., 1988; De Vita et al., 1989; Viglietto et al., 1990; 
Beutler et al., 1992; Calabro et al., 1993; Mason et 
al., 1995; Xu et al., 1995; Miwa et al., 1996; Okano 
et al., 2001; Taki et al., 2001; Beutler et al., 2002). 
Changes in this region may have an effect on the 
tetramer interface, which is mainly made by elec-
trostatic contacts. The V284A substitution neither 
changes the polarity of the amino-acid residue nor 
introduces a steric hindrance. A comparison of the 
minimized structures of the wild type and V284A 
mutant showed minor changes in the course of the 
main chain and no changes in the positions of the 
residues forming salt bridges, so this mutation does 
not cause serious structure distortions.
Figure 2A. Ribbon representation of human G6PD, ac-
cording to the crystal structure of the Canton mutant, 
PDB entry 1QKI (Au et al., 2000). 
Subunits of the enzyme are shown in dark and light blue. 
F191, colored yellow; V284, orange and I392, red are 
shown as spheres.
Figure 2B. Changes in the structure of human G6PD in-
duced by I392T mutation.
Wild type of human G6PD is shown as pink ribbon with 
R393, Y401 and W509 (sticks, colored in red). Ribbon of 
the mutated enzyme is shown in light blue; R393, Y401 
and W509 in dark blue.
Vol. 54       881Novel G6PD variants
I392 is located in the β+α domain at β-sheet L 
far away from the dimer interface (Fig. 2A). The side 
chain of I392 is directed away from the NADP+ crev-
ice, so it does not interfere directly with the NADP+ 
binding site. On the other hand, energy minimiza-
tion calculations show that the introduction of I392T 
mutation could change the orientation of residues 
R393, Y401 and W509 (Fig. 2B), which are in direct 
contact with the nicotinamide moiety of NADP+. 
This could influence protein function.
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